Product
Neratinib
Aliases
2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, HKI-272 Maleate (8 other aliases)
Name
neratinib
FDA Approved
Yes
33 clinical trials
1 organization
1 drug
64 indications
5 posters
1 document
Indication
Breast CancerIndication
NSCLCIndication
Breast NeoplasmIndication
Breast NeoplasmsIndication
Breast TumorsIndication
AngiosarcomaIndication
Triple-Negative Breast CancerIndication
Breast Cancer (HER2-positive)Indication
Breast Cancer Stage IIIIndication
Invasive Lobular Breast CarcinomaIndication
Hormone Receptor Positive TumorIndication
Hormone Receptor Negative TumorIndication
Locally Advanced Breast CancerIndication
Metastatic CancerIndication
HER2 gene mutationIndication
Malignant Solid NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Advanced Solid TumorIndication
Ovarian CancerIndication
HER2-positive breast cancerIndication
Hormone Receptor PositiveIndication
Breast Inflammatory CarcinomaIndication
Breast CarcinomaIndication
Stage III Breast CancerIndication
Stage IIIA Breast CancerIndication
Breast cancerIndication
Gastric Esophageal CancerIndication
Stomach CancerIndication
Biliary Tract NeoplasmsIndication
GlioblastomaIndication
Solid TumorIndication
Central Nervous System TumorIndication
lymphomaIndication
LeukemiaIndication
Triple-Negative Breast CarcinomaIndication
Malignant NeoplasmIndication
Breast Cancer, Stage IVIndication
Metastatic Malignant Solid NeoplasmIndication
Endometrial CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
EGFR gene amplificationIndication
EGFR gene mutationIndication
ERBB2 Gene AmplificationIndication
ERBB2 MutationIndication
ERBB3 gene mutationIndication
Erbb4 Gene MutationIndication
KRAS Gene MutationIndication
Neurofibromatosis Type 2Indication
Acoustic NeuromaIndication
SchwannomaIndication
MeningiomaIndication
EpendymomaIndication
Breast Cancer, Stage IIAIndication
Prostate CancerIndication
Castration-resistant Prostate CancerIndication
HER2-Positive Breast CarcinomaIndication
AdultDrug
NeratinibClinical trial
An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER MutationsStatus: Terminated, Estimated PCD: 2023-01-02
Clinical trial
A Single-arm, Open, Multicenter Phase II Clinical Study of Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain MetastasesStatus: Not yet recruiting, Estimated PCD: 2026-09-30
Clinical trial
An Open-Label Phase 2 Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibStatus: Completed, Estimated PCD: 2021-12-28
Clinical trial
A Single-arm, Open-label, Multicenter Phase II Clinical Study of Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
Neratinib in Patients With HER2+ Breast Cancer: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and SwitzerlandStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)Status: Recruiting, Estimated PCD: 2030-12-01
Clinical trial
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersStatus: Not yet recruiting, Estimated PCD: 2030-04-30
Clinical trial
Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, An Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab Biosimilar (Herzuma®) in Patients With HER2 Mutated Advanced Solid CancersStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 1/1b Clinical Trial of Niraparib and Neratinib in Advanced Solid Tumors With an Expansion Cohort in Platinum-resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Randomized Phase II Study to Evaluate the Incidence of Discontinuations Due to Diarrhoea at 3 Cycles in Patients With Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer Treated With Neratinib Plus Loperamide Prophylaxis Versus Neratinib With Initial Dose Escalation Plus PRN Loperamide Prophylaxis Versus Neratinib Plus Loperamide Plus Colesevelam Prophylaxis "DIANER Study"Status: Recruiting, Estimated PCD: 2025-03-25
Clinical trial
A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2021-07-20
Clinical trial
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBCStatus: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal CancersStatus: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 TrialStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 AlterationsStatus: Recruiting, Estimated PCD: 2024-06-17
Clinical trial
Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)Status: Recruiting, Estimated PCD: 2030-10-01
Clinical trial
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Pilot Clinical Trial Examining the Safety and Efficacy of Neratinib in Combination With Ruxolitinib in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer With Chest Wall RecurrenceStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)Status: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)Status: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without TrastuzumabStatus: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase 2 Study of Neratinib in Patients With Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) SignalingStatus: Withdrawn, Estimated PCD: 2021-09-24
Clinical trial
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2020-03-12
Clinical trial
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseaseStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestStatus: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated CancersStatus: Recruiting, Estimated PCD: 2024-12-31
Document
DailyMed Label: NerlynxOrganization
Puma Biotechnology, Inc.